PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke
Background: Stroke is a significant public health problem and a leading cause of death and long-term disability worldwide. Several treatments for ischemic stroke have been developed, but these treatments have limited effectiveness. One potential treatment for this condition is Actovegin<sup>®&...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/6/1623 |
| _version_ | 1827738441921593344 |
|---|---|
| author | Aurelian Anghelescu Florentina Carmen Firan Gelu Onose Constantin Munteanu Andreea-Iulia Trandafir Ilinca Ciobanu Ștefan Gheorghița Vlad Ciobanu |
| author_facet | Aurelian Anghelescu Florentina Carmen Firan Gelu Onose Constantin Munteanu Andreea-Iulia Trandafir Ilinca Ciobanu Ștefan Gheorghița Vlad Ciobanu |
| author_sort | Aurelian Anghelescu |
| collection | DOAJ |
| description | Background: Stroke is a significant public health problem and a leading cause of death and long-term disability worldwide. Several treatments for ischemic stroke have been developed, but these treatments have limited effectiveness. One potential treatment for this condition is Actovegin<sup>®</sup>/AODEJIN, a calf blood deproteinized hemodialysate/ultrafiltrate that has been shown to have pleiotropic/multifactorial and possibly multimodal effects. The actual actions of this medicine are thought to be mediated by its ability to reduce oxidative stress, inflammation, and apoptosis and to enhance neuronal survival and plasticity. Methods: To obtain the most up-to-date information on the effects of Actovegin<sup>®</sup>/AODEJIN in ischemic stroke, we systematically reviewed the literature published in the last two years. This review builds upon our previous systematic literature review published in 2020, which used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method to search for and select related articles over almost two decades, between 1 January 2001 and 31 December 2019. Additionally, we compared the results of our PRISMA search (human intelligence-based) with those obtained from an interrogation of a GPT-based chatbot (ChatGPT) in order to ensure comprehensive coverage of potentially relevant studies. Results: Our updated review found limited new evidence on the use of Actovegin<sup>®</sup>/AODEJIN in ischemic stroke, although the number of articles on this subject consistently increased compared to that from our initial systematic literature review. Specifically, we found five articles up to 2020 and eight more until December 2022. While these studies suggest that Actovegin<sup>®</sup>/AODEJIN may have neuroprotective effects in ischemic stroke, further clinical trials are needed to confirm these findings. Consequently, we performed a funnel analysis to evaluate the potential for publication bias. Discussion: Our funnel analysis showed no evidence of publication bias, suggesting that the limited number of studies identified was not due to publication bias but rather due to a lack of research in this area. However, there are limitations when using ChatGPT, particularly in distinguishing between truth and falsehood and determining the appropriateness of interpolation. Nevertheless, AI can provide valuable support in conducting PRISMA-type systematic literature reviews, including meta-analyses. Conclusions: The limited number of studies identified in our review highlights the need for additional research in this area, especially as no available therapeutic agents are capable of curing central nervous system lesions. Any contribution, including that of Actovegin (with consideration of a positive balance between benefits and risks), is worthy of further study and periodic reappraisal. The evolving advancements in AI may play a role in the near future. |
| first_indexed | 2024-03-11T02:44:25Z |
| format | Article |
| id | doaj.art-1608d48f09d942ad81851d752e83fc11 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T02:44:25Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-1608d48f09d942ad81851d752e83fc112023-11-18T09:25:55ZengMDPI AGBiomedicines2227-90592023-06-01116162310.3390/biomedicines11061623PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic StrokeAurelian Anghelescu0Florentina Carmen Firan1Gelu Onose2Constantin Munteanu3Andreea-Iulia Trandafir4Ilinca Ciobanu5Ștefan Gheorghița6Vlad Ciobanu7Faculty of Midwifery and Nursing, University of Medicine and Pharmacy “Carol Davila”, 020022 Bucharest, RomaniaThe Physical and Rehabilitation Medicine & Balneology Clinic Division—The NeuroRehabilitation Compartment, Teaching Emergency Hospital of the Ilfov County, 22104 Bucharest, RomaniaThe Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital “Bagdasar-Arseni”, 041915 Bucharest, RomaniaThe Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital “Bagdasar-Arseni”, 041915 Bucharest, RomaniaThe Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital “Bagdasar-Arseni”, 041915 Bucharest, RomaniaThe Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital “Bagdasar-Arseni”, 041915 Bucharest, RomaniaThe Neuromuscular Rehabilitation Clinic Division, Teaching Emergency Hospital “Bagdasar-Arseni”, 041915 Bucharest, RomaniaComputer Science Department, Politehnica University of Bucharest, 060042 Bucharest, RomaniaBackground: Stroke is a significant public health problem and a leading cause of death and long-term disability worldwide. Several treatments for ischemic stroke have been developed, but these treatments have limited effectiveness. One potential treatment for this condition is Actovegin<sup>®</sup>/AODEJIN, a calf blood deproteinized hemodialysate/ultrafiltrate that has been shown to have pleiotropic/multifactorial and possibly multimodal effects. The actual actions of this medicine are thought to be mediated by its ability to reduce oxidative stress, inflammation, and apoptosis and to enhance neuronal survival and plasticity. Methods: To obtain the most up-to-date information on the effects of Actovegin<sup>®</sup>/AODEJIN in ischemic stroke, we systematically reviewed the literature published in the last two years. This review builds upon our previous systematic literature review published in 2020, which used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) method to search for and select related articles over almost two decades, between 1 January 2001 and 31 December 2019. Additionally, we compared the results of our PRISMA search (human intelligence-based) with those obtained from an interrogation of a GPT-based chatbot (ChatGPT) in order to ensure comprehensive coverage of potentially relevant studies. Results: Our updated review found limited new evidence on the use of Actovegin<sup>®</sup>/AODEJIN in ischemic stroke, although the number of articles on this subject consistently increased compared to that from our initial systematic literature review. Specifically, we found five articles up to 2020 and eight more until December 2022. While these studies suggest that Actovegin<sup>®</sup>/AODEJIN may have neuroprotective effects in ischemic stroke, further clinical trials are needed to confirm these findings. Consequently, we performed a funnel analysis to evaluate the potential for publication bias. Discussion: Our funnel analysis showed no evidence of publication bias, suggesting that the limited number of studies identified was not due to publication bias but rather due to a lack of research in this area. However, there are limitations when using ChatGPT, particularly in distinguishing between truth and falsehood and determining the appropriateness of interpolation. Nevertheless, AI can provide valuable support in conducting PRISMA-type systematic literature reviews, including meta-analyses. Conclusions: The limited number of studies identified in our review highlights the need for additional research in this area, especially as no available therapeutic agents are capable of curing central nervous system lesions. Any contribution, including that of Actovegin (with consideration of a positive balance between benefits and risks), is worthy of further study and periodic reappraisal. The evolving advancements in AI may play a role in the near future.https://www.mdpi.com/2227-9059/11/6/1623ischemic strokechatbot/GPT (artificial intelligence—AI)deproteinized ultrafiltrate/hemodialysate compound ActoveginPRISMA-type systematic literature reviewmeta-analysis |
| spellingShingle | Aurelian Anghelescu Florentina Carmen Firan Gelu Onose Constantin Munteanu Andreea-Iulia Trandafir Ilinca Ciobanu Ștefan Gheorghița Vlad Ciobanu PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke Biomedicines ischemic stroke chatbot/GPT (artificial intelligence—AI) deproteinized ultrafiltrate/hemodialysate compound Actovegin PRISMA-type systematic literature review meta-analysis |
| title | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
| title_full | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
| title_fullStr | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
| title_full_unstemmed | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
| title_short | PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke |
| title_sort | prisma systematic literature review including with meta analysis vs chatbot gpt ai regarding current scientific data on the main effects of the calf blood deproteinized hemoderivative medicine actovegin in ischemic stroke |
| topic | ischemic stroke chatbot/GPT (artificial intelligence—AI) deproteinized ultrafiltrate/hemodialysate compound Actovegin PRISMA-type systematic literature review meta-analysis |
| url | https://www.mdpi.com/2227-9059/11/6/1623 |
| work_keys_str_mv | AT aureliananghelescu prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT florentinacarmenfiran prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT geluonose prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT constantinmunteanu prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT andreeaiuliatrandafir prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT ilincaciobanu prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT stefangheorghita prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke AT vladciobanu prismasystematicliteraturereviewincludingwithmetaanalysisvschatbotgptairegardingcurrentscientificdataonthemaineffectsofthecalfblooddeproteinizedhemoderivativemedicineactovegininischemicstroke |